HRP20180902T1 - Kristalni oblici modulatora receptora androgena - Google Patents
Kristalni oblici modulatora receptora androgena Download PDFInfo
- Publication number
- HRP20180902T1 HRP20180902T1 HRP20180902TT HRP20180902T HRP20180902T1 HR P20180902 T1 HRP20180902 T1 HR P20180902T1 HR P20180902T T HRP20180902T T HR P20180902TT HR P20180902 T HRP20180902 T HR P20180902T HR P20180902 T1 HRP20180902 T1 HR P20180902T1
- Authority
- HR
- Croatia
- Prior art keywords
- theta
- crystalline form
- prostate cancer
- pharmaceutical preparation
- xrpd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Kristalni Oblik B 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diazaspiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida, naznačen time da ima najmanje jedan od:
(a) spektar difrakcije X-zraka praha (XRPD), isti kao što je prikazan na Slici 2;
(b) spektar difrakcije X-zraka praha (XRPD), sa karakterističnim vrhovima na 12.1±0.1° 2-theta, 16.0±0.1° 2-theta, 16.7±0.1° 2-theta, 20.1±0.1° 2-theta, 20.3±0.1° 2-theta;
(c) parametre jedinične ćelije, koji su jednaki sljedećim, na -173°C:
(d) isti spektar difrakcije X-zraka praha (XRPD) kao što su (a) ili (b), poslije barem tjedan dana skladištenja na 40°C i 75% RV; ili
(e) isti spektar difrakcije X-zraka praha (XRPD) kao što su (a) ili (b), poslije 12 dana skladištenja na 25°C i 92% RH.
2. Kristalni oblik prema zahtjevu 1, naznačen time, da ima najmanje jedan od:
(f) termogram DSK, sličan onome koji je prikazan na Slici 11;
(g) termogram termo-gravimetrijske analize (TGA), sličan onome koji je prikazan na Slici 11; ili
(h) termogram DSK s endotermom, koji ima početnu temperaturu na 194°C.
3. Kristalni oblik prema zahtjevu 1 ili zahtjevu 2, naznačen time da navedeni kristalni oblik ima spektar difrakcije X-zraka praha (XRPD), s karakterističnim vrhovima na 12.1±0.1° 2-theta, 16.0±0.1° 2-theta, 16.7±0.1° 2-theta, 20.1±0.1° 2-theta, 20.3±0.1° 2-theta.
4. Kristalni oblik prema bilo kojem od zahtjeva 1-3, naznačen time da navedeni kristalni oblik ima spektar difrakcije X-zraka praha (XRPD) isti kao što je prikazan na Slici 2.
5. Kristalni oblik prema bilo kojem od zahtjeva 1-4, naznačen time da navedeni kristalni oblik ima parametre jedinične ćelije koji su jednaki sljedećim, na -173°C:
6. Kristalni oblik prema bilo kojem od zahtjeva 1-5, da je navedeni kristalni oblik nesolvatiziran.
7. Farmaceutski pripravak koja sadrži 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diazaspiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamid i najmanje jedan dodatni sastojak, koji se bira između farmaceutski prihvatljivih nosača, razrjeđivača i ekscipijenata, te pri tome ovaj 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diazaspiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamid u farmaceutskom pripravku se sastoji od kristalnog Oblika B, u skladu s bilo kojim od zahtjeva 1-6.
8. Farmaceutski pripravak prema zahtjevu 7, naznačen time da je navedeni farmaceutski pripravak u obliku pogodnom za oralno davanje sisavcu.
9. Farmaceutski pripravak prema zahtjevu 8, naznačen time da navedeni farmaceutski pripravak predstavlja kruti oblik za oralnog doziranje.
10. Farmaceutski pripravak prema bilo kojem od zahtjeva 7-9, naznačen time da navedeni farmaceutski pripravak sadrži od 0.5 mg do 1000 mg kristalnog 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diazaspiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida.
11. Farmaceutski pripravak prema bilo kojem od zahtjeva 7-10 naznačen time da je za upotrebu za liječenje raka prostate kod sisavca.
12. Farmaceutski pripravak prema zahtjevu 11, naznačen time da rak prostate predstavlja hormonski senzibilan rak prostate ili hormonski refraktorni rak prostate.
13. Kristalni oblik 4-[7-(6-cijano-5-trifluorometilpiridin-3-il)-8-okso-6-tiokso-5,7-diazaspiro[3.4]okt-5-il]-2-fluoro-N-metilbenzamida za upotrebu prema bilo kojem od zahtjeva 1-6, naznačen time da je za liječenje raka prostate kod humanog subjekta.
14. Kristalni oblik za upotrebu prema zahtjevu 13, naznačen time da rak prostate predstavlja hormonski senzibilan rak prostate ili hormonski refraktorni rak prostate.
15. Farmaceutska kompozicija prema zahtjevu 8, naznačen time da sisavca predstavlja ljudsko biće.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261656888P | 2012-06-07 | 2012-06-07 | |
| EP13800681.2A EP2858985B1 (en) | 2012-06-07 | 2013-06-04 | Crystalline forms of an androgen receptor modulator |
| PCT/US2013/044116 WO2013184681A1 (en) | 2012-06-07 | 2013-06-04 | Crystalline forms of an androgen receptor modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180902T1 true HRP20180902T1 (hr) | 2018-08-24 |
Family
ID=49712550
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180902TT HRP20180902T1 (hr) | 2012-06-07 | 2013-06-04 | Kristalni oblici modulatora receptora androgena |
| HRP20201387TT HRP20201387T1 (hr) | 2012-06-07 | 2020-08-31 | Kristalni oblici modulatora receptora androgena |
| HRP20210909TT HRP20210909T1 (hr) | 2012-06-07 | 2021-06-08 | Kristalni oblici modulatora androgenih receptora |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201387TT HRP20201387T1 (hr) | 2012-06-07 | 2020-08-31 | Kristalni oblici modulatora receptora androgena |
| HRP20210909TT HRP20210909T1 (hr) | 2012-06-07 | 2021-06-08 | Kristalni oblici modulatora androgenih receptora |
Country Status (45)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461343B2 (en) | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| JP2015505856A (ja) | 2011-12-16 | 2015-02-26 | オレマ ファーマシューティカルズ インク． | 新規のベンゾピラン化合物、その組成物および使用 |
| WO2013184681A1 (en) | 2012-06-07 | 2013-12-12 | Aragon Pharmaceuticals, Inc. | Crystalline forms of an androgen receptor modulator |
| EP3971167A1 (en) | 2012-09-11 | 2022-03-23 | Medivation Prostate Therapeutics LLC | Formulations of enzalutamide |
| MY180834A (en) | 2012-09-26 | 2020-12-10 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| JP2017525727A (ja) * | 2014-08-26 | 2017-09-07 | アスター バイオテック リミテッド ライアビリティ カンパニー | プロテインキナーゼ阻害剤 |
| AU2015358497B2 (en) | 2014-12-05 | 2021-04-29 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
| CA2969656A1 (en) * | 2014-12-05 | 2016-06-09 | Aragon Pharmaceuticals, Inc. | Solid formulations of arn-509 and hydroxypropyl methylcellulose acetate succinate |
| HUE051888T2 (hu) | 2014-12-05 | 2021-03-29 | Aragon Pharmaceuticals Inc | Rákellenes készítmények |
| WO2016100905A1 (en) | 2014-12-19 | 2016-06-23 | Lutron Electronics Co., Inc. | Multi-channel lighting fixture having multiple light-emitting diode drivers |
| CR20180600A (es) | 2016-06-03 | 2019-07-11 | Aragon Pharmaceuticals Inc | Composiciones anticancerigenas |
| WO2018112001A1 (en) | 2016-12-13 | 2018-06-21 | Watson Laboratories Inc. | Solid state forms of apalutamide |
| BR112020007439A2 (pt) | 2017-10-16 | 2020-10-27 | Aragon Pharmaceuticals, Inc. | antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastática |
| WO2019135254A1 (en) * | 2018-01-02 | 2019-07-11 | Mylan Laboratories Limited | Apalutamide polymorphs and their preparation thereof |
| US20200270226A1 (en) * | 2018-06-20 | 2020-08-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of arn-509, preparation method and use thereof |
| WO2020049598A2 (en) | 2018-09-08 | 2020-03-12 | Cipla Limited | Apalutamide polymorphs |
| IT201900003839A1 (it) | 2019-03-15 | 2020-09-15 | Olon Spa | Sintesi di apalutamide amorfa stabile |
| WO2020234817A1 (en) * | 2019-05-21 | 2020-11-26 | Laurus Labs Limited | Polymorphic forms of apalutamide and its preparation thereof |
| IT201900010593A1 (it) * | 2019-07-01 | 2021-01-01 | Dipharma Francis Srl | Forma cristallina di un inibitore di recettori degli androgeni |
| EP4017848A1 (en) * | 2019-08-22 | 2022-06-29 | Dr. Reddy's Laboratories Ltd. | Process for the preparation of apalutamide |
| IT201900015974A1 (it) | 2019-09-10 | 2021-03-10 | Olon Spa | Apalutamide cristallina stabile in forma pura e processo per la sua preparazione |
| CN110590740A (zh) * | 2019-09-20 | 2019-12-20 | 武汉大学 | 一种阿帕鲁胺化合物及其药物制剂 |
| EP4541786A2 (en) | 2020-09-04 | 2025-04-23 | Synthon B.V. | Improved process for preparation of apalutamide |
| CN112679468A (zh) * | 2021-01-05 | 2021-04-20 | 四川科伦药物研究院有限公司 | 阿帕他胺的晶体形式、制备方法和用途 |
| WO2023143090A1 (zh) * | 2022-01-25 | 2023-08-03 | 成都苑东生物制药股份有限公司 | 一种阿帕他胺溶剂化物新晶型及其制备方法 |
| CN115536634B (zh) * | 2022-10-17 | 2024-06-11 | 上海博悦生物科技有限公司 | 一种阿帕他胺的合成方法 |
| CN116332907A (zh) * | 2023-03-16 | 2023-06-27 | 奥锐特药业股份有限公司 | 一种无定形阿帕他胺的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| LT3412290T (lt) | 2006-03-27 | 2021-04-26 | The Regents Of The University Of California | Androgeno receptorių moduliatorius, skirtas prostatos vėžio bei su androgeno receptoriais susijusių ligų gydymui |
| SG170809A1 (en) | 2006-03-29 | 2011-05-30 | Univ California | Diarylthiohydantoin compounds |
| US8461343B2 (en) | 2007-03-27 | 2013-06-11 | Sloan-Kettering Institute For Cancer Research | Synthesis of thiohydantoins |
| EP2536708A4 (en) * | 2010-02-16 | 2013-05-29 | Aragon Pharmaceuticals Inc | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF |
| WO2013184681A1 (en) * | 2012-06-07 | 2013-12-12 | Aragon Pharmaceuticals, Inc. | Crystalline forms of an androgen receptor modulator |
| US20200270226A1 (en) | 2018-06-20 | 2020-08-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of arn-509, preparation method and use thereof |
-
2013
- 2013-06-04 WO PCT/US2013/044116 patent/WO2013184681A1/en active Application Filing
- 2013-06-04 CA CA3114726A patent/CA3114726A1/en active Pending
- 2013-06-04 KR KR1020197033592A patent/KR102195916B1/ko active Active
- 2013-06-04 EP EP19169275.5A patent/EP3533792B1/en active Active
- 2013-06-04 LT LTEP13800681.2T patent/LT2858985T/lt unknown
- 2013-06-04 BR BR112014030678A patent/BR112014030678A2/pt not_active Application Discontinuation
- 2013-06-04 PE PE2019002096A patent/PE20200725A1/es unknown
- 2013-06-04 DK DK19169275.5T patent/DK3533792T3/da active
- 2013-06-04 SM SM20210355T patent/SMT202100355T1/it unknown
- 2013-06-04 RS RS20210739A patent/RS61988B1/sr unknown
- 2013-06-04 PT PT181574351T patent/PT3348553T/pt unknown
- 2013-06-04 CR CR20190331A patent/CR20190331A/es unknown
- 2013-06-04 MY MYPI2014703627A patent/MY187500A/en unknown
- 2013-06-04 SI SI201331010T patent/SI2858985T1/sl unknown
- 2013-06-04 UA UAA201702779A patent/UA123142C2/uk unknown
- 2013-06-04 SG SG10201610249TA patent/SG10201610249TA/en unknown
- 2013-06-04 RS RS20200913A patent/RS60617B1/sr unknown
- 2013-06-04 PT PT138006812T patent/PT2858985T/pt unknown
- 2013-06-04 PL PL19169275T patent/PL3533792T3/pl unknown
- 2013-06-04 SG SG10201610248SA patent/SG10201610248SA/en unknown
- 2013-06-04 RS RS20180680A patent/RS57370B1/sr unknown
- 2013-06-04 SG SG11201408140QA patent/SG11201408140QA/en unknown
- 2013-06-04 CA CA3008345A patent/CA3008345C/en active Active
- 2013-06-04 EA EA201992010A patent/EA201992010A1/ru unknown
- 2013-06-04 UA UAA201500086A patent/UA115665C2/uk unknown
- 2013-06-04 HK HK15111086.5A patent/HK1210175A1/xx unknown
- 2013-06-04 PE PE2014002383A patent/PE20150631A1/es active IP Right Grant
- 2013-06-04 IN IN10084DEN2014 patent/IN2014DN10084A/en unknown
- 2013-06-04 PE PE2020000234A patent/PE20200795A1/es unknown
- 2013-06-04 SI SI201331788T patent/SI3348553T1/sl unknown
- 2013-06-04 CN CN201380041652.3A patent/CN104619692A/zh active Pending
- 2013-06-04 ME MEP-2018-158A patent/ME03081B/me unknown
- 2013-06-04 KR KR1020157000266A patent/KR102062024B1/ko active Active
- 2013-06-04 IL IL267608A patent/IL267608B1/en unknown
- 2013-06-04 ES ES13800681.2T patent/ES2670683T3/es active Active
- 2013-06-04 SM SM20200496T patent/SMT202000496T1/it unknown
- 2013-06-04 HU HUE19169275A patent/HUE054595T2/hu unknown
- 2013-06-04 EP EP21171579.2A patent/EP3922629A1/en active Pending
- 2013-06-04 HU HUE13800681A patent/HUE038082T2/hu unknown
- 2013-06-04 MX MX2014015005A patent/MX356754B/es active IP Right Grant
- 2013-06-04 DK DK18157435.1T patent/DK3348553T3/da active
- 2013-06-04 EA EA201492272A patent/EA028791B1/ru unknown
- 2013-06-04 EA EA201791592A patent/EA033956B1/ru unknown
- 2013-06-04 HR HRP20180902TT patent/HRP20180902T1/hr unknown
- 2013-06-04 TW TW102119817A patent/TWI532732B/zh active
- 2013-06-04 NZ NZ717683A patent/NZ717683A/en unknown
- 2013-06-04 CN CN201610202980.2A patent/CN105693692A/zh active Pending
- 2013-06-04 PL PL13800681T patent/PL2858985T3/pl unknown
- 2013-06-04 LT LTEP18157435.1T patent/LT3348553T/lt unknown
- 2013-06-04 EP EP13800681.2A patent/EP2858985B1/en active Active
- 2013-06-04 SM SM20180311T patent/SMT201800311T1/it unknown
- 2013-06-04 DK DK13800681.2T patent/DK2858985T3/en active
- 2013-06-04 JP JP2015516121A patent/JP6182209B2/ja active Active
- 2013-06-04 SI SI201331894T patent/SI3533792T1/sl unknown
- 2013-06-04 TR TR2018/08939T patent/TR201808939T4/tr unknown
- 2013-06-04 NZ NZ702203A patent/NZ702203A/en unknown
- 2013-06-04 CN CN202110417935.XA patent/CN113135892A/zh active Pending
- 2013-06-04 CA CA3055660A patent/CA3055660A1/en not_active Abandoned
- 2013-06-04 AU AU2013271751A patent/AU2013271751B2/en active Active
- 2013-06-04 PT PT191692755T patent/PT3533792T/pt unknown
- 2013-06-04 US US14/406,520 patent/US9481663B2/en active Active
- 2013-06-04 ES ES19169275T patent/ES2875932T3/es active Active
- 2013-06-04 LT LTEP19169275.5T patent/LT3533792T/lt unknown
- 2013-06-04 HU HUE18157435A patent/HUE050357T2/hu unknown
- 2013-06-04 EP EP18157435.1A patent/EP3348553B1/en not_active Revoked
- 2013-06-04 ME MEP-2020-163A patent/ME03815B/me unknown
- 2013-06-04 PL PL18157435T patent/PL3348553T3/pl unknown
- 2013-06-04 IL IL320522A patent/IL320522A/en unknown
- 2013-06-04 ES ES18157435T patent/ES2809738T3/es active Active
- 2013-06-04 CA CA2875767A patent/CA2875767C/en active Active
-
2014
- 2014-12-01 CR CR20140549A patent/CR20140549A/es unknown
- 2014-12-04 PH PH12014502714A patent/PH12014502714B1/en unknown
- 2014-12-04 IL IL236055A patent/IL236055A0/en unknown
- 2014-12-04 NI NI201400142A patent/NI201400142A/es unknown
- 2014-12-05 GT GT201400283A patent/GT201400283A/es unknown
- 2014-12-05 EC ECIEPI201430098A patent/ECSP14030098A/es unknown
- 2014-12-05 CL CL2014003331A patent/CL2014003331A1/es unknown
- 2014-12-09 CO CO14270612A patent/CO7240407A2/es unknown
-
2015
- 2015-01-06 ZA ZA2015/00076A patent/ZA201500076B/en unknown
-
2016
- 2016-07-26 PH PH12016501470A patent/PH12016501470B1/en unknown
- 2016-09-12 US US15/262,522 patent/US9994545B2/en active Active
- 2016-12-19 HK HK16114389.2A patent/HK1226066A1/zh unknown
-
2017
- 2017-01-17 AU AU2017200298A patent/AU2017200298B2/en active Active
- 2017-02-15 JP JP2017025746A patent/JP6345821B2/ja active Active
- 2017-12-22 AU AU2017279807A patent/AU2017279807B2/en active Active
-
2018
- 2018-05-09 US US15/975,449 patent/US10308630B2/en active Active
- 2018-05-23 JP JP2018098638A patent/JP2018141009A/ja active Pending
- 2018-05-31 IL IL259738A patent/IL259738B/en active IP Right Grant
- 2018-07-06 CY CY20181100712T patent/CY1120393T1/el unknown
-
2019
- 2019-04-15 US US16/384,002 patent/US10526310B2/en active Active
- 2019-07-10 US US16/507,780 patent/US10556882B2/en active Active
- 2019-12-11 US US16/710,785 patent/US10766875B2/en active Active
-
2020
- 2020-06-15 IL IL275413A patent/IL275413A/en unknown
- 2020-07-29 US US16/942,069 patent/US10934271B2/en active Active
- 2020-08-31 HR HRP20201387TT patent/HRP20201387T1/hr unknown
- 2020-09-23 CY CY20201100901T patent/CY1123427T1/el unknown
-
2021
- 2021-01-26 US US17/158,806 patent/US12018008B2/en active Active
- 2021-06-08 HR HRP20210909TT patent/HRP20210909T1/hr unknown
- 2021-07-02 CY CY20211100595T patent/CY1124831T1/el unknown
- 2021-11-02 LU LU00236C patent/LUC00236I2/fr unknown
- 2021-11-02 NO NO2021046C patent/NO2021046I1/no unknown
- 2021-11-03 LT LTPA2021525C patent/LTPA2021525I1/lt unknown
- 2021-11-03 NL NL301144C patent/NL301144I2/nl unknown
- 2021-11-03 FR FR21C1050C patent/FR21C1050I2/fr active Active
- 2021-11-04 CY CY2021032C patent/CY2021032I2/el unknown
- 2021-11-04 HU HUS2100047C patent/HUS2100047I1/hu unknown
-
2024
- 2024-05-13 US US18/662,345 patent/US20250092011A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180902T1 (hr) | Kristalni oblici modulatora receptora androgena | |
| EA201290734A1 (ru) | Рифаксимин в форме порошка, способ его получения и композиции контролируемого высвобождения, содержащие указанный рифаксимин, полезные для достижения длительного эффекта | |
| CR20200532A (es) | Compuestos de heteroarilo tetracíclicos | |
| MX363715B (es) | Formas solidas de un inhbidor de cdk4/6 selectivo. | |
| DK2104490T3 (da) | Mikroniserede partikler af aktive bestanddele med lavdosis-styrke til pulverformuleringer til inhalation | |
| MX2020002924A (es) | Lactamas fusionadas de arilo y heteroarilo. | |
| PH12014500943A1 (en) | Combination treatment of cancer | |
| EA200901277A1 (ru) | Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина | |
| SI2451445T1 (sl) | Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino | |
| CU24355B1 (es) | Derivados de 2((( oxadiazol/triazol/tetrazol/isoxazol) metil) fenil)-1-(heterociclil)-ona como inhibidores activos de autotaxina | |
| EP2419138A4 (en) | GEL COMPOSITIONS FOR THE ADMINISTRATION OF PHARMACEUTICALLY ACTIVE COMPOUNDS | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| HK1213779A1 (zh) | 用於立即和延长释放的组合物 | |
| IL226398B (en) | Pharmaceutical formulations containing corticosteroids for administration on the skin | |
| PH12012502445A1 (en) | Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| CA2894715C (en) | Diazole amides | |
| MX2015011536A (es) | Nuevos antagonistas de receptores trpa1 de sulfamidas. | |
| TN2020000009A1 (en) | Estrogen receptor modulators | |
| PH12015501301A1 (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
| WO2015071761A3 (en) | Crystalline forms b, c, and d of canagliflozin | |
| JO3084B1 (ar) | تشكيل كريستال دلتا لملح الأرجينين من البيريندوبريل وطريقة إعداد مستحضرات ومركبات دوائية تشتمل عليه | |
| UA105285C2 (uk) | Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання | |
| MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
| IN2014DN07898A (hr) |